Development and Evaluation of Nanoemulsion of Primaquine for Prevention of Relapsing Malaria

  • Mohsina Khan Oriental College of Pharmacy and Research, Oriental University, Indore (M. P.)
  • Gulfisha Shaikh Oriental College of Pharmacy and Research, Oriental University, Indore (M. P.)
  • M K Gupta Oriental College of Pharmacy and Research, Oriental University, Indore (M. P.)
  • Gurdeep Singh Oriental College of Pharmacy and Research, Oriental University, Indore (M. P.)

Abstract

Malaria relapsing refers to the reactivation of the infection via Relapse, when symptoms reappear after the parasites have been eliminated from blood but persist as dormant hypnozoites in liver cells. Malaria relapse commonly occurs between 8–24 w and is commonly seen with P. Vivax and P. Ovale infections. Primaquine (PQ) is one of the most widely used antimalarial and is t he only available drug till date to combat relapsing form of malaria especially in case of Plasmodium Vivax and Plasmodium Ovale. Primaquine acts specifically on the pre-erythrocytic schizonts which are concentrated predominantly in the liver and causes relapse after multiplication but one of the major drawback of this drug is that it dissolves in less proportion in systemic circulation to show an active effect. So to reduce these effects, Primaquine incorporated into oral lipid nanoemulsion having particle size in the range of 10–200 nm. The absorbtion capacity of primaquine is significantly increased as nanoemulsion of Primaquine used. The drug is readily absorbed by the liver 45% more than before. So the results declared the successful absorbtion of primaquine by the liver in its nenoemulsion form as it will be used further in the treatment of malaria because it is less toxic.

Keywords: Relapsing malaria, Nanoemulsion, Primaquine, Pre-erythrocytic schizonts

References

1. Campbell C C. Malaria: an emerging and re-emerging global plague. FEMS Immunology Medical and Microbiology. 1997; 18:325–31.
2. Pink R, Hudson A, Mouries M. A and Bendig M. Opportunities and challenges in antiparasitic drug discovery. Nature Reviews Drug
Discovery. 2005; 4: 727–40.
3. Baird, J. K, Hoffman, S. L. Primaquine therapy for malaria. Clinical Infectious Diseases. 2004; 39:1336–1345.
4. Povinelli L, Monson T. A, Fox B . C, Parise M. E., Morrisey J. M and Vaidya A. B. Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis. Journal of Travel Medicine. 2003; 10:353–355.
5. Thiagarajan P, Theaj R and Prakash U. Nanoemulsions for drug delivery through different routes. Resear ch in Biotechnology. 2011; 2 (3): 01-13.
6. Huabing C, Chalermchai K, Xiangliang Y and Xueling C. Nanonization strategies for poorly water-soluble drugs. Drug Discovery Today. 2011;
16 (7-8): 354-60.
7. Hardainiyan S. A short review on promising trends employed for preparation of nanoemulsions in food applications. Asian Journal of Microbiology, Food Science and Biotechnological Innovations (ASIO-JMFSBI). 2015; 1(1): 26-30.
8. Gaspar R, Preat V and Roland M. Nanoparticles of polyisohexylcyanoacrylate (PIHCA) as carriers of primaquine formulation, physico-chemical characterization and acute toxicity. International Journal Pharmacy. 1991; 68:111-19.
9. Pirson P, Steiger R and Trouet A. The disposition of free and liposomally encapsulated antimalarial primaquine in mice. Biochemical Pharmacology. 1982; 31: 3501-507.
10. Stjärnkvist P. Biodegradable microspheres: XIV effect of microparticle bound primaquine on L. donovani in mice. International Journal Pharmacy. 2008; 347: 136-43.
11. White N. J. A. Short review on antimalarial drug resistance. The Journal of Clinical Investigation 2004; 113: 1084-1092
Statistics
79 Views | 137 Downloads
How to Cite
Mohsina Khan, Gulfisha Shaikh, M K Gupta, and Gurdeep Singh. “Development and Evaluation of Nanoemulsion of Primaquine for Prevention of Relapsing Malaria”. Current Research in Pharmaceutical Sciences, Vol. 9, no. 4, Jan. 2020, pp. 73-76, doi:10.24092/CRPS.2019.090404.
Section
Research Articles